JPRN-UMIN000036395已完成1 期
Phase I / IIa trial of R-OKY-034F for pancreatic cancer patients - Phase I / IIa trial of R-OKY-034F for pancreatic cancer patients
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Duplicate cancer Patients with active double cancer. However, we do not exclude duplicate cancers that do not affect safety and efficacy assessment. 2) Items related to complications * Patients with unstable angina (angina pectoris onset or attack worsening within 3 weeks before enrollment), or patients with a history of myocardial infarction within 6 months * Patients with QtcE prolongation of 450 ms or more * Patients with interstitial lung disease or patients with previous history * Patients with high degree of disability due to respiratory disease (interstitial lung disease, radiation lung injury etc.) (grade 3 or higher on the modified MRC scale) * Patients with high physical activity restriction due to heart failure (NYHA class III or higher) * Patients with intestinal paralysis, intestinal obstruction or severe diarrhea * Patients who have the following abnormal values for kidney function, liver function and bone marrow function at screening test - Moderate or higher renal dysfunction with GFR estimate less than 45 ml / min / 1.73 m2 - Moderate or more liver dysfunction, with either AST or ALT> 100 IU / L - Leukocytes: less than 3,000 / microL - Neutrophils: less than 1,500 /microL - Platelet: less than 75,000 / microL - Hemoglobin: less than 8.0 g / dL - Total bilirubin: 2.5 mg / dL or more * Patients weighing less than 40 kg * Pregnant women * Breastfeeding women (It is not this limitation if it is possible to refrain from breastfeeding for 14 days after the final oral administration from the study drug oral administration start date) * Patients who are complicated by psychosis or psychiatric symptoms and judged as difficult to participate in clinical trials 3) Other * Women and men who can not agree to the practice of highly effective contraception * Patients who the investigator or subinvestigator judged as inappropriate for trial entry
研究者
相似试验
进行中（未招募）
不适用
orwegian Pancreatic Cancer TrialResectable pancreatic cancerMedDRA version: 18.0Level: LLTClassification code 10033604Term: Pancreatic cancerSystem Organ Class: 100000004864EUCTR2015-001635-21-NOorwegian Gastointestinal Cancer Group
招募中
2 期
Phase II study of FOLFOX for unresectable pancreatic cancer patients with germline BRCA pathogenic variantJPRN-jRCT1061230031Ioka Tatsuya33
进行中（未招募）
1 期
orPACT-1Resectable pancreatic cancerMedDRA version: 20.0Level: LLTClassification code 10007071Term: Cancer of head of pancreasSystem Organ Class: 100000004864EUCTR2015-001635-21-SESwedish studygroup for pancreatic cancer (SSPAC)126
进行中（未招募）
1 期
ordic Pancreatic Cancer TrialResectable pancreatic cancerMedDRA version: 21.0Level: LLTClassification code 10033604Term: Pancreatic cancerSystem Organ Class: 100000004864EUCTR2015-001635-21-DKorwegian Gastointestinal Cancer Group140
已完成
2 期
Phase 2a trial of GBS-01 for advanced pancreatic cancer refractory to gemcitabine and fluoropyrimidine chemotherapy.Advanced pancreatic cancer refractory to gemcitabine and fluoropyrimidine chemotherapyJPRN-UMIN000010111ational Cancer Center Hospital East47